Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

ASO Author Reflections: Implementing a Program of Talimogene laherparepvec.

Collichio F.

Ann Surg Oncol. 2018 Nov 12. doi: 10.1245/s10434-018-7030-4. [Epub ahead of print] No abstract available.

PMID:
30421049
2.
3.

Internal medicine fellowship directors' perspectives on the quality and utility of letters conforming to residency program director letter of recommendation guidelines.

O'Connor AB, Williams CM, Dalal B, Sulistio MS, Roth TK, Milne CK, Collichio FA, Muchmore EA, Alweis R.

J Community Hosp Intern Med Perspect. 2018 Aug 23;8(4):173-176. doi: 10.1080/20009666.2018.1500424. eCollection 2018.

4.

Implementing a Program of Talimogene laherparepvec.

Collichio F, Burke L, Proctor A, Wallack D, Collichio A, Long PK, Ollila DW.

Ann Surg Oncol. 2018 Jul;25(7):1828-1835. doi: 10.1245/s10434-018-6361-5. Epub 2018 Feb 7.

PMID:
29417403
5.

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

D'Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, Pavlick AC, Lewis KD, Weil SC, Heyburn J, Schweizer C, O'Shannessy DJ, Carvajal RD.

Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11.

PMID:
29127533
6.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL.

J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.

7.

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.

Kaufman HL, Andtbacka RHI, Collichio FA, Wolf M, Zhao Z, Shilkrut M, Puzanov I, Ross M.

J Immunother Cancer. 2017 Sep 19;5(1):72. doi: 10.1186/s40425-017-0276-8.

8.

Integrating Palliative and Oncology Care for Patients with Advanced Cancer: A Quality Improvement Intervention.

Hanson LC, Collichio F, Bernard SA, Wood WA, Milowsky M, Burgess E, Creedle CJ, Cheek S, Chang L, Chera B, Fox A, Lin FC.

J Palliat Med. 2017 Dec;20(12):1366-1371. doi: 10.1089/jpm.2017.0100. Epub 2017 Jul 24.

PMID:
28737996
9.

Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.

Naqash AR, Stroud G, Collichio FA, Muzaffar M, Sharma N, Walker P.

Acta Oncol. 2017 Oct;56(10):1327-1330. doi: 10.1080/0284186X.2017.1324212. Epub 2017 May 8. No abstract available.

PMID:
28481677
10.

Imaging Manifestations of Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene Laherparepvec: Initial Experience.

Zamora C, Lopez M, Cunningham F, Collichio F, Castillo M.

AJNR Am J Neuroradiol. 2017 Jun;38(6):1218-1222. doi: 10.3174/ajnr.A5206. Epub 2017 Apr 20.

11.

The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.

Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, Lee CB, Collichio FA, Fried D, Marks LB, Chera BS.

Anticancer Drugs. 2017 Jul;28(6):669-675. doi: 10.1097/CAD.0000000000000497.

PMID:
28368903
12.

Guidelines for a Standardized Fellowship Letter of Recommendation.

Alweis R, Collichio F, Milne CK, Dalal B, Williams CM, Sulistio MS, Roth TK, Muchmore EA.

Am J Med. 2017 May;130(5):606-611. doi: 10.1016/j.amjmed.2017.01.017. Epub 2017 Feb 9. No abstract available.

PMID:
28189466
13.

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.

Harrington KJ, Andtbacka RH, Collichio F, Downey G, Chen L, Szabo Z, Kaufman HL.

Onco Targets Ther. 2016 Nov 16;9:7081-7093. eCollection 2016.

14.

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.

Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, Chen L, Shilkrut M, Kaufman HL.

Ann Surg Oncol. 2016 Dec;23(13):4169-4177. Epub 2016 Jun 24.

15.

Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma.

Franceschi AM, Moschos SJ, Anders CK, Glaubiger S, Collichio FA, Lee CB, Castillo M, Lee YZ.

J Comput Assist Tomogr. 2016 Sep-Oct;40(5):803-5. doi: 10.1097/RCT.0000000000000420.

16.

Medical Knowledge Assessment by Hematology and Medical Oncology In-Training Examinations Are Better Than Program Director Assessments at Predicting Subspecialty Certification Examination Performance.

Collichio FA, Hess BJ, Muchmore EA, Duhigg L, Lipner RS, Haist S, Hawley JL, Morrison CA, Clayton CP, Raymond MJ, Kayoumi KM, Gitlin SD.

J Cancer Educ. 2017 Sep;32(3):647-654. doi: 10.1007/s13187-016-0993-6.

PMID:
26897634
17.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS.

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

PMID:
26014293
18.

The Next Accreditation System: a strategy for implementing new reporting standards using a Hematology/Oncology model.

Collichio F, Kayoumi K, Sierra L, Clayton CP, Raymond M, Muchmore EA.

Am J Med. 2015 Feb;128(2):200-7. doi: 10.1016/j.amjmed.2014.10.025. Epub 2014 Oct 30. No abstract available.

PMID:
25448172
19.

Unanticipated hospital admissions during or soon after radiation therapy: Incidence and predictive factors.

Waddle MR, Chen RC, Arastu NH, Green RL, Jackson M, Qaqish BF, Camporeale J, Collichio FA, Marks LB.

Pract Radiat Oncol. 2015 May-Jun;5(3):e245-53. doi: 10.1016/j.prro.2014.08.004. Epub 2014 Sep 17.

PMID:
25413398
20.

Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab.

Baker JJ, Stitzenberg KB, Collichio FA, Meyers MO, Ollila DW.

Am Surg. 2014 Aug;80(8):805-10. Review.

PMID:
25105403
21.

Oncology fellows’ career plans, expectations, and well-being: do fellows know what they are getting into?

Shanafelt TD, Raymond M, Horn L, Moynihan T, Collichio F, Chew H, Kosty MP, Satele D, Sloan J, Gradishar WJ.

J Clin Oncol. 2014 Sep 20;32(27):2991-7.

22.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

23.

Historical review of melanoma treatment and outcomes.

Lee C, Collichio F, Ollila D, Moschos S.

Clin Dermatol. 2013 Mar-Apr;31(2):141-7. doi: 10.1016/j.clindermatol.2012.08.015. Review.

PMID:
23438377
24.

Vemurafenib-associated pancreatitis: case report.

Muluneh B, Buie LW, Collichio F.

Pharmacotherapy. 2013 Apr;33(4):e43-4. doi: 10.1002/phar.1208. Epub 2013 Feb 22.

PMID:
23436544
25.

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.

O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A.

J Clin Oncol. 2013 Mar 20;31(9):1211-8. doi: 10.1200/JCO.2012.44.5585. Epub 2013 Feb 11.

PMID:
23401447
26.

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

Irvin WJ Jr, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC.

Clin Breast Cancer. 2010 Dec 1;10(6):465-70. doi: 10.3816/CBC.2010.n.061.

27.

How to organize a fellowship program: lessons learned and how to include accreditation council for graduate medical education competencies in the curriculum.

Collichio FA, Kosty MP, Moynihan TJ, Davis TH, Stewart JA.

J Clin Oncol. 2010 Aug 1;28(22):3659-67. doi: 10.1200/JCO.2010.28.1964. Epub 2010 Jul 6. No abstract available.

PMID:
20606079
28.

Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.

Dillon P, Thomas N, Sharpless N, Collichio F.

Med Oncol. 2010 Dec;27(4):1127-32. doi: 10.1007/s12032-009-9348-z. Epub 2009 Nov 5.

29.

Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?

Kimple RJ, Grabowski S, Papez M, Collichio F, Ewend MG, Morris DE.

Am J Clin Oncol. 2010 Jun;33(3):265-70. doi: 10.1097/COC.0b013e3181a76a24.

PMID:
19823072
30.

Developing an in-training examination for fellows: the experience of the American Society of Clinical Oncology.

Collichio FA, Kayoumi KM, Hande KR, Hawkins RE, Hawley JL, Adelstein DJ, D'Angelo JM, Stewart JA.

J Clin Oncol. 2009 Apr 1;27(10):1706-11. doi: 10.1200/JCO.2008.20.3091. Epub 2009 Feb 17.

PMID:
19224843
31.

Shackled: the challenge of caring for an incarcerated patient.

Courtwright A, Raphael-Grimm T, Collichio F.

Am J Hosp Palliat Care. 2008 Aug-Sep;25(4):315-7. doi: 10.1177/1049909108315912.

PMID:
18768426
32.

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.

Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ.

Cancer Chemother Pharmacol. 2008 Dec;63(1):99-107. doi: 10.1007/s00280-008-0716-8. Epub 2008 Mar 8.

33.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

34.

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.

Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Dees EC.

Cancer Chemother Pharmacol. 2007 Oct;60(5):759-66. Epub 2007 Feb 7.

35.

Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer.

Kwock L, Smith JK, Castillo M, Ewend MG, Collichio F, Morris DE, Bouldin TW, Cush S.

Lancet Oncol. 2006 Oct;7(10):859-68. Review.

PMID:
17012048
36.

Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA.

Clin Breast Cancer. 2006 Aug;7(3):237-43.

PMID:
16942640
37.

Concomitant pregnancy and breast cancer: options for systemic therapy.

Kelly HL, Collichio FA, Dees EC.

Breast Dis. 2005-2006;23:95-101. Review.

PMID:
16823172
38.

Axillary lymph node count is lower after neoadjuvant chemotherapy.

Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N.

Am J Surg. 2006 Jun;191(6):827-9.

PMID:
16720159
39.

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.

Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML.

J Natl Cancer Inst. 2005 Aug 3;97(15):1137-42.

PMID:
16077072
40.

High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Klauber-Demore N, Kuzmiak C, Rager EL, Ogunrinde OB, Ollila DW, Calvo BF, Kim HJ, Meyer A, Dees C, Graham M 2nd, Collichio FA, Sartor CI, Metzger R, Carey LA.

Am J Surg. 2004 Oct;188(4):386-9.

PMID:
15474431
41.

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer.

Dees EC, McKinnon KP, Kuhns JJ, Chwastiak KA, Sparks S, Myers M, Collins EJ, Frelinger JA, Van Deventer H, Collichio F, Carey LA, Brecher ME, Graham M, Earp HS, Serody JS.

Cancer Immunol Immunother. 2004 Sep;53(9):777-85. Epub 2004 Jun 8.

PMID:
15185007
42.

Breaking bad news.

Block KI, Bugno TJ, Collichio FA, Geffen J, Schapira L.

Integr Cancer Ther. 2003 Mar;2(1):39-62. No abstract available.

PMID:
12941167
43.

Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer.

Collichio FA, Amamoo MA, Fogleman J, Griggs J, Graham M.

Am J Clin Oncol. 2002 Apr;25(2):194-7.

PMID:
11943902
44.

Pregnancy after breast cancer: from psychosocial issues through conception.

Collichio FA, Agnello R, Staltzer J.

Oncology (Williston Park). 1998 May;12(5):759-65, 769; discussion 770, 773-5. Review.

45.
46.

An atypical case of plasma cell leukemia.

Newman CL, Collichio FA, Bennett JM.

Leuk Res. 1997 Oct;21(10):1003-6. No abstract available.

PMID:
9403012
47.

Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival.

Collichio F, Pandya K.

Oncology (Williston Park). 1994 Dec;8(12):45-52. Review.

PMID:
7888312
48.

Management of patients with small cell carcinoma and the syndrome of ectopic corticotropin secretion.

Collichio FA, Woolf PD, Brower M.

Cancer. 1994 Mar 1;73(5):1361-7.

PMID:
8111702
49.

Supplemental Content

Loading ...
Support Center